For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses o ...
Oral ivarmacitinib, administered 4 mg or 8 mg once daily, significantly induced hair regrowth at 24 weeks vs. placebo in ...
For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable, according to a study presented at the ...
HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8mg is efficacious and tolerable, according to a study ...
In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...
HealthDay on MSN3d
American Academy of Dermatology, March 7 to 11The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...
The response rate difference versus placebo was 25.6% and 31.6%, respectively, for ivarmacitinib 4 mg and 8 mg, with no reported deaths, thromboembolic events, or major cardiovascular events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback